Introduction
The results of a clinical trial of lenvatinib were published in the Lancet earlier this year [1] . According to the results, the response rate was higher for lenvatinib than for any other known molecular targeted agents in hepatocellular carcinoma (HCC) patients. The response rates based on independent imaging review and investigator review according to the modified RECIST (mRECIST) assessment were extremely high at 40.6 and 24.1%, respectively. The response rate based on independent imaging review according to RECIST 1.1 was also high (18.8%) ( Table 1 ). The response to locoregional treatment (e.g., transcatheter arterial chemoembolization [TACE] and ablation) is correlated with overall survival (OS). In a meta-analysis of seven studies, Vincenzi et al. [2] showed that the hazard ratio (HR) for OS was 0.39 (95% confidence interval [CI] 0.26-0.61, p < 0.0001) when comparing responders and nonresponders among 1,352 patients treated with TACE (n = 1,236), cryoablation (n = 64), and bland transarterial embolization (n = 57). This excellent HR indicated the correlation between response to locoregional therapy and OS benefit (Fig. 1) . It is established evidence that OS benefit is more prominent in responders to locoregional therapy than in nonresponders evaluated by mRECIST; thus, the evidence that objective response measured by mRECIST predicts survival in patients receiving locoregional therapies is currently recommended in the EASL guidelines [3] . Regarding molecular targeted agents, most sorafenib-treated patients show stable disease, demonstrating the survival benefit of sorafenib treatment. However, the asso- 
Retrospective Studies of Sorafenib
Ronot et al. [4] examined 64 sorafenib-treated HCC patients, and found that the median OS was 25.5 months in 18 patients with objective response (objective response rate [ORR] 28.1%), 13.3 months in 29 patients with stable disease, and 5.7 months in 29 patients with progressive disease, according to the mRECIST criteria; OS was significantly longer in responders than in nonresponders (p < 0.001). Arizumi et al. [5] retrospectively analyzed 158 sorafenib-treated patients, and found significantly better OS in responders (patients with complete response or partial response, 25.4 months) than in patients with short stable disease (5.7 months) and progressive disease (7.3 months) (p < 0.0001). Edeline et al. [6] analyzed sorafenib-treated patients with unresectable HCC, and reported a median OS of 18 months in 12 responders (response rate, 22.6%), which was significantly longer than the median OS of 8 months in 41 nonresponders (p = 0.013). In a retrospective analysis of 191 sorafenibtreated patients, Takada et al. [7] identified 25 responders according to mRECIST, and showed that OS was significantly longer (p = 0.0117) in these patients (22 months) than in nonresponders (10 months) ( Table 2 ). However, because these studies were all retrospective analyses, the levels of evidence provided are not high.
Association between Response to Molecular Targeted Agents and Survival Benefit Demonstrated by Prospective Controlled Trials
Lencioni et al. [8] performed a responder analysis using data from a Phase III trial of brivanib as second-line therapy. Among 226 brivanib-treated patients, 26 were responders according to mRECIST (ORR 11.5%); OS was 15.0 months in responders, which was significantly longer than the OS of 9.4 months in nonresponders (HR 0.31, 95% CI 0.16-0.60, p < 0.001). Multivariable analysis confirmed that objective response evaluated according to mRECIST was a clear independent predictor of survival. Furthermore, the authors reported that survival becomes more favorable with increasing ORR and longer duration of response.
Meyer et al. [9] analyzed pooled data of the Phase II part of two multicenter open-label Phase I and randomized Phase II studies (nintedanib 200 mg twice daily versus sorafenib 400 
mg twice daily) carried out independently in Asia and Europe to examine the association of response (according to RECIST 1.0 or mRECIST) with survival. Of 180 patients, 28 were responders (response rate, 15.6%), with a median OS of 16.7 months, whereas 152 showed no response and had a median OS of 10.9 months; OS was significantly better in responders than in nonresponders (HR 0.544, 95% CI 0.335-0.881, p = 0.0122).
Multivariable analysis showed that response according to mRECIST was an independent predictor of survival, albeit only with a trend toward significance (HR 0.62, 95% CI 0.38-1.01, p = 0.053), roughly supporting the results of the multivariable analysis reported by Lencioni et al. [8] . Kudo et al. [10] conducted the SILIUS study (a prospective controlled trial), and reported that 18 out of 96 patients who received sorafenib monotherapy were responders (response rate, 18.8%); OS was 27.2 months in these patients, which was significantly longer than the OS of 8.9 months in nonresponders (p < 0.001).
The correlation between response and survival suggests that the quality of evidence is high, because this was clearly proven by responder analysis using the database developed from the above three prospective randomized controlled trials (Table 3 ). This evidence can be applied to the interpretation of a high lenvatinib response rate. Lenvatinib has a high response rate (40.6%), and may therefore offer survival benefit to more than 3-fold as many patients as other agents.
Responder analysis in the SILIUS study showed a response rate of 36% in the sorafenib plus arterial infusion chemotherapy group, which was twice as high as that in the sorafenib only group. In addition, the study indicated that the improvement in survival was comparable between the two groups as long as patients responded to the respective therapies. In other words, the survival benefit is more frequently observed in patients who received sorafenib plus arterial infusion chemotherapy because it has a demonstrably higher response rate. Because lenvatinib has an even higher response rate than sorafenib plus arterial infusion chemotherapy, its survival benefit should apply to a higher proportion of patients, suggesting lenvatinib is a potential alternative to arterial infusion chemotherapy. In addition, the ORR of lenvatinib is similar to the world standard ORR of TACE therapy (Fig. 2) [11] [12] [13] , indicating that it could replace TACE in certain populations of intermediate-stage HCC patients in the very near future.
ORR of Lenvatinib in the Japanese Subpopulation from the REFLECT Trial
The ORR of lenvatinib in a Japanese subpopulation from the REFLECT trial was reported as 46.9% (sorafenib, ORR = 12.6%), which is considerably higher than the ORR of 40.6% in the overall population of the REFLECT trial (Table 4) [14] . In addition, the ORR in patients with Barcelona Clinic Liver Cancer (BCLC) intermediate stage was markedly higher (61.3%) Values are % unless otherwise indicated. * nominal. ( Fig. 2, 3) than the ORR by world standard of TACE, which was 42% in the placebo arm from the BRISK-TA trial or two other trials [11] [12] [13] , and much higher than the ORR of 52% for the first TACE session in real-world practice in Japan according to the OPTIMIS study (Fig. 4 ) [14] [15] [16] . Furthermore, progression-free survival in the intermediate-stage HCC patients was 9.1 months, which is considerably longer than that of the overall cohort at 7.4 months (Fig. 3) .
Therefore, initial treatment with lenvatinib followed by on-demand TACE when necessary may be a good strategy in patients who are likely to become TACE failure in order to preserve liver function and improve OS in BCLC intermediate-stage HCC (Fig. 5, 6 ; Table 5 ). The "Kindai criteria," a new subclassification of BCLC B stage, which recently updated the original version of the Kinki criteria in 2018, is more suitable for treatment decision-making in the intermediate-stage HCC patients than the original version of the Kinki criteria (Table 5 ). Lenvatinib may be the first treatment option in patients with bilobar multifocal intermediate-stage HCC based on its extremely higher ORR (40.6% in the overall cohort and 61.3% in the Japanese intermediate-stage subpopulation) than that of TACE (Figs. 3, 4, 5, 7) . 
